CLINICAL TRIALS PROFILE FOR DURACLON
✉ Email this page to a colleague
All Clinical Trials for DURACLON
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00349921 ↗ | Clonidine Versus Adenosine to Treat Neuropathic Pain | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | 2004-08-01 | The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain. |
NCT00349921 ↗ | Clonidine Versus Adenosine to Treat Neuropathic Pain | Completed | Wake Forest School of Medicine | Phase 2 | 2004-08-01 | The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain. |
NCT00349921 ↗ | Clonidine Versus Adenosine to Treat Neuropathic Pain | Completed | Wake Forest University Health Sciences | Phase 2 | 2004-08-01 | The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain. |
NCT00510016 ↗ | Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome | Completed | Johns Hopkins University | Phase 2 | 2002-07-01 | To test the hypothesis that the combination of the tincture of opium (DTO) and clonidine will be more effective in treating infants with neonatal abstinence syndrome (opioid withdrawal) than tincture of opium (DTO) alone. |
NCT00510016 ↗ | Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 2002-07-01 | To test the hypothesis that the combination of the tincture of opium (DTO) and clonidine will be more effective in treating infants with neonatal abstinence syndrome (opioid withdrawal) than tincture of opium (DTO) alone. |
NCT00678379 ↗ | Pediatric Tonsillectomy Pain Reduction Study | Completed | Vanderbilt University Medical Center | Phase 3 | 2008-04-01 | Tonsillectomy is associated with a significant decrease quality of life in children secondary to pain, which is worsened with swallowing. The objective of the current study is to conduct a prospective, double-blind, placebo-controlled, randomized clinical trial using a pre-tonsillectomy infiltration of the tonsillar fossa comparing three treatment regimens in reducing post-tonsillectomy morbidity (i.e. pain, poor oral intake): 1) Placebo (saline injection) 2) bupivacaine (0.5%) + lidocaine (1%), 3) bupivacaine (0.5%) + lidocaine (1%) + clonidine (25 µg). |
NCT01360450 ↗ | Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants | Terminated | National Institute on Drug Abuse (NIDA) | Phase 2/Phase 3 | 2011-07-01 | Thousands of critically ill infants (and children) are exposed to opioids and benzodiazepines to achieve sedation and analgesia as part of routine care in neonatal and pediatric intensive care units. While the use of these agents are undisputedly beneficial in reducing pain and anxiety, improving ventilation, reducing pulmonary vascular resistance and improving outcomes; the consequence is often the development of tolerance and physiologic dependence - similar to prenatal exposure from these same classes of drugs. The investigators have recently reported the results of randomized placebo control trial showing that the addition of clonidine (central alpha 2 agonist) to tapering doses of opioids was efficacious and safe in treating opioid dependence in infants who had moderate to severe neonatal abstinence syndrome from prenatal drug exposure to opioids. Currently, the investigators propose to perform a double-blind, randomized placebo control trial in a cohort of critically ill infants without prenatal drug exposure at Johns Hopkins Hospital to test the overall hypothesis that early addition of clonidine to a cohort of critically ill neonates on mechanical ventilation who are receiving opioids and benzodiazepines for analgesia and sedation will be efficacious and safe in reducing both the incidence and severity of withdrawal symptoms (NICU-NAS); as well as, reducing the time to complete sedative and analgesic drug detoxification. The hypothesis will be tested by addressing 2 specific aims that will determine: 1) the efficacy and safety of clonidine in critically ill infants, and 2) pharmacokinetics and pharmacodynamics using population-based pharmacokinetics in this vulnerable infant population who have only been exposed to these drugs as part of their routine care. Many "standard of care practices" are incorporated in neonatal and pediatric care prior to evidence based studies. This proposal will fill a much needed gap in translating what the investigators have learned about basic mechanisms mediating dependence and withdrawal to proven therapies for vulnerable pediatric populations. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DURACLON
Condition Name
Clinical Trial Locations for DURACLON
Trials by Country
Clinical Trial Progress for DURACLON
Clinical Trial Phase
Clinical Trial Sponsors for DURACLON
Sponsor Name